COVID-19 and hypertension: risks and management. A scientific statement on behalf of the British and Irish Hypertension Society

J Hum Hypertens. 2021 Apr;35(4):304-307. doi: 10.1038/s41371-020-00451-x. Epub 2021 Jan 22.
No abstract available

MeSH terms

  • Angiotensin Receptor Antagonists / pharmacology*
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology*
  • Antihypertensive Agents / pharmacology
  • COVID-19* / epidemiology
  • COVID-19* / therapy
  • Evidence-Based Practice / standards*
  • Humans
  • Hypertension* / drug therapy
  • Hypertension* / epidemiology
  • Ireland
  • Patient Care Management / methods*
  • Patient Safety
  • Risk Assessment
  • Severity of Illness Index
  • Societies, Medical / standards
  • United Kingdom

Substances

  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents